Business Description
Citius Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US17322U2078
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 55.97 | |||||
Equity-to-Asset | 0.88 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 18.4 | |||||
3-Year EPS without NRI Growth Rate | 21.2 | |||||
3-Year FCF Growth Rate | 23.7 | |||||
3-Year Book Growth Rate | -1.9 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 17.54 | |||||
9-Day RSI | 25.16 | |||||
14-Day RSI | 28.9 | |||||
6-1 Month Momentum % | -76.81 | |||||
12-1 Month Momentum % | -80.43 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 6.75 | |||||
Quick Ratio | 6.75 | |||||
Cash Ratio | 4.31 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -41.9 | |||||
Shareholder Yield % | 0.8 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -43.68 | |||||
ROA % | -38.35 | |||||
ROIC % | -55.85 | |||||
ROC (Joel Greenblatt) % | -1008.6 | |||||
ROCE % | -43.35 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 30.48 | |||||
PB Ratio | 0.28 | |||||
Price-to-Tangible-Book | 1.41 | |||||
EV-to-EBIT | -0.21 | |||||
EV-to-Forward-EBIT | 1.55 | |||||
EV-to-EBITDA | -0.21 | |||||
EV-to-Forward-Revenue | 0.37 | |||||
EV-to-FCF | -0.3 | |||||
Price-to-Net-Current-Asset-Value | 1.44 | |||||
Price-to-Net-Cash | 3.7 | |||||
Earnings Yield (Greenblatt) % | -476.19 | |||||
FCF Yield % | -113.73 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Citius Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -5.559 | ||
Beta | 0.71 | ||
Volatility % | 96.98 | ||
14-Day RSI | 28.9 | ||
14-Day ATR (€) | 0.136568 | ||
20-Day SMA (€) | 3.29 | ||
12-1 Month Momentum % | -80.43 | ||
52-Week Range (€) | 3.1225 - 23.325 | ||
Shares Outstanding (Mil) | 7.73 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Citius Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Citius Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Citius Pharmaceuticals Inc Frequently Asked Questions
What is Citius Pharmaceuticals Inc(FRA:47N0)'s stock price today?
When is next earnings date of Citius Pharmaceuticals Inc(FRA:47N0)?
Does Citius Pharmaceuticals Inc(FRA:47N0) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |